Bosch-Barrera J, Pérez-Montoyo H, Domènech C, Lizcano JM
Understanding Ibrilatazar's mechanism of action: Addressing concerns about autophagy in cancer Therapy
Lung Cancer . 2025 May:203:108538
DOI: 10.1016/j.lungcan.2025.108538
IF: 4.40
RESEARCH GROUPS
Protein kinases in cancer research
1
Number of publications
100.00
%
% Q1
0.00
%
% D1
0.00
%
% Leadership
0.00
%
% Female Leadership
8.17
CROWN (2021-2025)
23.08
%
HCP10% (2021-2025)
100.00
%
% Open access
100.00
%
% International Collaboration
1
Highly cited papers / HCP 1% (2021-2025)
1
Publications in high-IF journals with high Altmetric scores
0
Number of Ongoing Projectes (total)
0
International ongoing projects
0
Number of New projects (total)
0
International new projects
0
Number of Active clinical Trials
0
Number of New Clinical Trials
0
Number of Theses
Our team is committed to unravelling novel cellular signaling pathways that govern cancer cell proliferation and differentiation, with the goal of developing targeted therapies to enhance the effectiveness of anticancer treatments. During 2025, we have identified the protein kinase ERK5 as a key contributor to the immunosuppressive environment of uterine carcinosarcoma, an aggressive endometrial cancer with very poor prognosis. In parallel, we continued collaborating with a Biopharma company on the clinical development of the fist-in-class anticancer compound ABTL0812, a pro-autophagy molecule currently evaluated in a Phase 2b clinical trial for pancreatic cancer. During the 2025, we published the results of the ENDOLUNG Phase 2 trail, demonstrating that the combination of ABTL0812 with carboplatin/paclitaxel is safe and exhibits good antitumor activity in patients with advanced squamous non-small cell lung cancer.
CORE/MISSIONS
- Rare Diseases
PROGRAMS
TEAM
Group Leader
Jose Miguel Lizcano de Vega
Principal Investigator (PI)
Jose Miguel Lizcano de Vega
Researchers
Lorena Usero Redrejo
PhD Students
Maria Viñas Casas, Clàudia Faúndez Vidiella, Idoia Bolinaga Ayala, Maria Arbat i Jubinyà, Marc Montoursi Picas
SELECTED PUBLICATIONS
Bosch-Barrera J, Estévez-García P, Martín-Martorell P, Sabatier R, Nadal E, Sais E, Gascón P, Oaknin A, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfón J, Domènech C, Morán T.
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer
Lung Cancer . 2025 Mar:201:108105
DOI: 10.1016/j.lungcan.2025.108105
IF: 4.4
SELECTED PROJECTS
Incremento del potencial clínico de Ibrilatazar: avanzar hacia un tratamiento transformador contra el cáncer
Principal Investigator: Jose Miguel Lizcano de Vega
Agency: Ministerio de Ciencia e Innovación.Proyectos de Colaboración Público-Privada 2024
Funding: 566,359 €
Period: 2025-2028
Nuevas terapias anticáncer basadas en las propiedades inmunomoduladoras de inhibidores farmacológicos de MAPK ERK5 (IMMUNONCOERK5)
Principal Investigator: Jose Miguel Lizcano de Vega
Agency: Ministerio de Ciencia e Innovación. Proyectos de Generación de Conocimiento 2022
Funding: 162,500 €
Period: 2023-2026
Efectos inmumoduladores de ABTL0812, un compuesto antitumoral activador de autofagia en fase clínica 2. Identificación de compuestos inmunoterapéuticos antitumorales basados en la autofagia
Principal Investigator: Jose Miguel Lizcano de Vega
Agency: MICINN. Proyectos Líneas Estratégicas 2022
Funding: 451,150 €
Period: 2022-2025
PATENTS
DISSEMINATION ACTIVITIES
